Related Experiment Video

Updated: Aug 10, 2026

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

Monoclonal Antibodies for the Treatment of Nasal Polyps

Thomas J Willson1, Robert M Naclerio2, Stella E Lee1

  • 1Department of Otolaryngology, Head & Neck Surgery, University of Pittsburgh Medical Center, 1400 Locust Street, Suite 2100, Building D, Pittsburgh, PA 15219, USA.

Immunology and Allergy Clinics of North America
|April 4, 2017
PubMed

Insights

Novel biologic therapies target specific inflammatory pathways for chronic rhinosinusitis (CRS) with nasal polyps. These advanced treatments aim to control severe disease and improve symptoms by modulating the immune system.

Area of Science:

  • Immunology
  • Pharmacology
  • Otolaryngology

Background:

  • Biologics represent a new class of targeted therapies for inflammatory conditions.
  • Chronic rhinosinusitis (CRS) with nasal polyps is a severe inflammatory disease.
  • Current treatments for CRS with nasal polyps have limitations.

Purpose of the Study:

  • To review biologic therapies investigated for chronic rhinosinusitis (CRS) with nasal polyps.
  • To summarize the mechanisms of action of these novel agents.
  • To discuss the potential of biologics in managing severe CRS.

Main Methods:

  • Literature review of studies on biologics for CRS with nasal polyps.
  • Analysis of inflammatory pathways targeted by these therapies.
  • Summary of clinical investigations and outcomes.

Main Results:

  • Biologics modulate key inflammatory pathways (e.g., IL-4, IL-5, IL-13, IgE).
  • Investigational biologics show promise in reducing polyp burden and improving sinonasal symptoms.
  • Targeted therapy offers potential for disease control in severe CRS.

Conclusions:

  • Biologics offer a promising targeted approach for severe chronic rhinosinusitis (CRS) with nasal polyps.
  • These novel therapies may provide significant disease control and symptomatic relief.
  • Further research is ongoing to establish the role of biologics in CRS management.
Keywords:
Allergic rhinitisAsthmaBiologicsChronic rhinosinusitisNasal polyps

More Related Videos

Generation of Monoclonal Antibodies Against Natural Products12:15

Generation of Monoclonal Antibodies Against Natural Products

Published on: April 6, 2019

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium09:45

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Published on: May 18, 2021

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...